Boston Scientific Sales Growth Slows to 1.5 Percent

The Tip Desk · October 28, 2026 · 3 min read

Third-quarter net sales were $5.138 billion, and the company now sees fourth-quarter sales down 3.0% to 1.0% versus a year earlier.

Boston Scientific Corporation (BSX) generated net sales of $5.138 billion in the third quarter of 2026, growing 1.5 percent on a reported, operational and organic basis versus the year-ago period, a sharp slowdown from 7.5 percent reported growth in the second quarter.

The medical-technology company reported GAAP net income attributable to common stockholders of $582 million, or $0.40 a share, compared with $755 million, or $0.51 a share, a year earlier. Adjusted earnings were $0.73 a share, versus $0.75 a year earlier.

Chairman and Chief Executive Officer Mike Mahoney said the year had been challenging and that global teams had worked to restore operations after a cybersecurity incident.

Gross profit was $3.428 billion, down from $3.542 billion a year earlier. Operating income was $828 million, compared with $1.048 billion. The company recorded $81 million of litigation-related net charges, $63 million of restructuring net charges and $39 million of intangible asset impairment charges in the quarter.

Both reportable segments slowed. Cardiovascular net sales were $3.406 billion, up 1.9 percent on a reported, operational and organic basis, after 7.8 percent organic growth in the second quarter. MedSurg sales were $1.733 billion, up 0.7 percent organically, after 5.4 percent organic growth in the second quarter.

Within MedSurg, Neuromodulation sales were $331 million, up 13.0 percent organically. Endoscopy sales were $741 million, down 0.6 percent organically, and Urology sales were $661 million, down 3.1 percent organically.

By region, United States sales were $3.309 billion, up 0.5 percent reported and operationally, after 6.2 percent growth in the second quarter. EMEA sales were $829 million, up 6.1 percent operationally. Asia-Pacific sales were $797 million, down 0.6 percent reported and 1.1 percent operationally, after 11.2 percent growth in the second quarter. Latin America and Canada sales were $203 million, up 10.5 percent operationally.

The company now estimates full-year 2026 net sales growth of approximately 4.25 percent on a reported basis and approximately 3.75 percent on an organic basis. It now estimates adjusted EPS of $3.16 to $3.18.

For the fourth quarter, Boston Scientific estimates net sales will decline approximately 3.0 percent to 1.0 percent versus the prior-year period on a reported and organic basis, with adjusted EPS of $0.77 to $0.79. The company said it has not provided reconciliations of forward-looking adjusted EPS guidance to GAAP guidance because the combined impact of items such as intangible asset impairment, acquisition-related charges, restructuring and litigation-related charges is uncertain and could be material.

The company commenced enrollment in the Elite AF trial of the next-generation WATCHMAN Elite left atrial appendage closure device. It received FDA 510(k) clearances for two StoneSmart technologies and an expanded size offering of the SEISMIQ peripheral intravascular lithotripsy catheter. It also entered a collaboration with Heartflow on CT-guided planning for percutaneous coronary intervention.